Life (Jan 2023)

First-Trimester Maternal Serum Adiponectin/Leptin Ratio in Pre-Eclampsia and Fetal Growth

  • Victoria E. de Knegt,
  • Paula L. Hedley,
  • Anna K. Eltvedt,
  • Sophie Placing,
  • Karen Wøjdemann,
  • Anne-Cathrine Shalmi,
  • Line Rode,
  • Jørgen K. Kanters,
  • Karin Sundberg,
  • Ann Tabor,
  • Ulrik Lausten-Thomsen,
  • Michael Christiansen

DOI
https://doi.org/10.3390/life13010130
Journal volume & issue
Vol. 13, no. 1
p. 130

Abstract

Read online

The serum adiponectin/leptin ratio (A/L ratio) is a surrogate marker of insulin sensitivity. Pre-eclampsia (PE) is associated with maternal metabolic syndrome and occasionally impaired fetal growth. We assessed whether the A/L ratio in first-trimester maternal serum was associated with PE and/or birth weight. Adiponectin and leptin were quantitated in first-trimester blood samples (gestational week 10+3–13+6) from 126 women who later developed PE with proteinuria (98 mild PE; 21 severe PE; 7 HELLP syndrome), and 297 controls, recruited from the Copenhagen First-Trimester Screening Study. The A/L ratio was reduced in PE pregnancies, median 0.17 (IQR: 0.12–0.27) compared with controls, median 0.32 (IQR: 0.19–0.62) (p p β = −0.165, p β = 2.98, p < 0.05), while adiponectin was not significantly associated. Our findings suggest that an impairment of the A/L ratio (as seen in metabolic syndrome) in the first trimester is characteristic of PE, while aberrant fetal growth in PE is not dependent on insulin sensitivity, but rather on leptin-associated pathways.

Keywords